{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:13Z","timestamp":1792292593705,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["75A50120C00001"],"award-info":[{"award-number":["75A50120C00001"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgar.2025.04.027","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T18:53:52Z","timestamp":1746298432000},"page":"271-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro activity of omadacycline against bacterial isolates from bone\/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015\u20132023)"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":false,"given":"Michael D.","family":"Huband","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley A.","family":"Fedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Blankers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.04.027_bib0001","year":"2024","journal-title":"WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance"},{"key":"10.1016\/j.jgar.2025.04.027_bib0002","unstructured":"CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: CDC; 2019 Available at: 2019 Antibiotic Resistance Threats Report | Antimicrobial Resistance | CDC."},{"key":"10.1016\/j.jgar.2025.04.027_bib0003","unstructured":"FDA. 2024. Antibacterial susceptibility test interpretive criteria. Administration USFDA, Washington, D.C. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"10.1016\/j.jgar.2025.04.027_bib0004","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.04.027_bib0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.04.027_bib0006","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0007","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0008","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0009","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0010","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of Omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0011","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2025.04.027_bib0012","doi-asserted-by":"crossref","first-page":"e02262","DOI":"10.1128\/AAC.02262-18","article-title":"Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)","volume":"63","author":"Carvalhaes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.04.027_bib0014","doi-asserted-by":"crossref","first-page":"e00018","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0015","doi-asserted-by":"crossref","first-page":"e02411","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of Omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","article-title":"Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014)","volume":"90","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","article-title":"Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0018","doi-asserted-by":"crossref","first-page":"e02327","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0019","doi-asserted-by":"crossref","first-page":"e02489","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019","volume":"27","author":"Pfaller","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.04.027_bib0021","doi-asserted-by":"crossref","first-page":"116711","DOI":"10.1016\/j.diagmicrobio.2025.116711","article-title":"Surveillance of omadacycline against 35,000 bacterial clinical isolaaltes from the United States (2019-2023)","volume":"111","author":"Huband","year":"2025","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0022","unstructured":"Miller L.G., Controlled trial of omadacycline randomized treatment given for bone and joint infection (CORGI). ClinicalTrials.Gov identifier: NCT05753215. Updated March 10, 2025. Accessed April 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05753215?term=NCT05753215&rank=1."},{"key":"10.1016\/j.jgar.2025.04.027_bib0023","unstructured":"Real world efficacy and safety analysis of omadacycline for the treatment of diabetic foot infections and acute myelitis. ClinicalTrials.Gov identifier:NCT04714411. Updated November 20, 2024. Accessed April 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04714411?term=NCT04714411&rank=1."},{"key":"10.1016\/j.jgar.2025.04.027_bib0024","series-title":"M07Ed12. methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2024"},{"key":"10.1016\/j.jgar.2025.04.027_bib0025","unstructured":"CLSI. 2024. M100Ed34. Performance standards for antimicrobial susceptibility testing: 34th informational supplement. CLSI, Wayne, PA."},{"key":"10.1016\/j.jgar.2025.04.027_bib0026","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jac\/dkac055","article-title":"Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis","volume":"77","author":"Gill","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.027_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01703-21","article-title":"Activity of omadacycline in rat methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Karau","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0029","doi-asserted-by":"crossref","first-page":"e01784","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.027_bib0030","unstructured":"Bhayani N., Couch K., Koo C., Young E., Stock K., John J., et al. Real-world outpatient use of omadacycline for bone and joint infections. 7th Annual Texas Medical Center AMR & Stewardship Conference; 2024 January 17-19; Houston, TX."},{"key":"10.1016\/j.jgar.2025.04.027_bib0031","unstructured":"Al Musawa M., Sinclair E., Frens Jeremy J., Molina Kyle C., Holger Dana J., Bouchard J., et al. Evaluation of Omadacycline treatment for osteomyelitis. ID week; 2024 October 16-19; Los Angeles, CA."},{"key":"10.1016\/j.jgar.2025.04.027_bib0032","unstructured":"Safety of Omadacycline versus standard-of-care oral antibiotic treatment for bone and joint infections: interim results from an open-label, non-inferiority, randomized controlled trial IDWeek 2024 October 16-20, 2024 Los Angeles, CA."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:25Z","timestamp":1762610365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"alternative-id":["S2213716525001031"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.027","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of omadacycline against bacterial isolates from bone\/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015\u20132023)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}